Citeline Japan Awards 2024 - Enter Now!

15 July Deadline

 
• By Ian Haydock and Lisa Takagi
  
Generate a summary of this article
Listen to this article
Beta

The 15 July entry deadline for the Citeline Japan Awards 2024 in Tokyo is fast approaching, so here's a reminder to take a look at the categories and criteria and be sure you get those submissions in by this date. Sponsorship opportunities and tables are also available. 

cliteline japan awards banner
15 July deadline for Citeline Japan Awards Entries • Source: Citeline

(Japanese follows English.) The Citeline Japan Awards 2024 will take place at the Palace Hotel in Tokyo on 22 October. This will be the third year for our growing Awards event in Japan, which has met with great success and much interest from the industry in this key global pharma market.

The entry deadline of 15 July is fast approaching so if you are thinking about making an entry, please take a look at the categories and criteria and submit your entry forms for the seven enterable categories by this date.

These include Best New Drug, Executive of the Year, Biotech Company of the Year, Best Contract Research Organization, Best Contract Development Manufacturing Organization, Licensing Deal of the Year, and Financing Deal of the Year.

Nominations can also be made for Pharma Company of the Year and the Lifetime Achievement Award, for which the winners are decided by a senior Citeline team.

The benefits of making an entry include exposure for your company through possible shortlisting and of course any final winners as decided by our distinguished independent judging panel would benefit from receiving the prestigious award and the recognition that comes from this.

A full guide on the criteria for each category and how to make an entry, along with all other information on the event, are available in English and Japanese at the links below. Also take this chance to book your table for the awards ceremony, which provides a great networking opportunity as well as an enjoyable evening at a wonderful venue in the heart of Tokyo.

Thank you and we look forward to seeing you there in October!

Citeline · Citeline Japan Awards 2024 - Enter Now! (Bilingual English/Japanese)

Open Media

(Japanese)

日本から世界の製薬市場やバイオテック市場で活躍する企業をたたえるイベント、Citeline Japan Awards は、おかげさまで3回目を迎え、今回も2024年10月22日にパレスホテル東京で開催します。

今回の表彰カテゴリーは、

  • 最も優れた新薬を表彰するBest New Drug
  • 最も活躍した経営者や幹部を表彰するExecutive of the Year 
  • 目覚ましい活躍を見せたバイオテック企業を表彰するBiotech Company of the Year
  • 最も優れたCRO、そしてCDMOをそれぞれたたえるBest CRO、Best CDMO
  • 最も注目された導出、導入の契約案件を選出するLicensing Deal of the Year
  • 優れた協業、買収契約案件を選出するFinancing Deal of the Year

の、7つとなっています。アワードは、運営企業から独立した専門家のチームが厳正な審査を行い、受賞者を決定します。

エントリーの期限は7月15日まで。エントリーを検討されるかたは、ぜひお早めに、概要欄のリンクから、日本語版または英語版のガイドラインをご覧ください。

あわこれら7つのカテゴリーのほか、最も活躍した製薬企業をたたえるPharma Company of the Year、長いキャリアを通じて製薬業界に貢献した人物をたたえるLifetime Achievement Awardの受賞者を独自に選出いたします。

本アワードは、日本の製薬・バイオテック業界という舞台で、たがいに切磋琢磨しながら活躍するさまざまな企業の参加者たちとディナーやカクテルを楽しみながら、今後の人脈を広げていただく場にもなっております。

また、エントリーだけでなく、ぜひ会場のテーブルをご予約いただき、ご来場ください。

English-language Awards site: https://www.citeline.com/en/awards/citelinejapanawards

Japanese-language Awards site: https://www.citeline.com/ja-jp/awards/citelinejapanawards

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Japan

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts

 
• By Lisa Takagi

Several major Japanese firms, including Takeda, are planning layoffs at home and elsewhere as they make efforts to streamline their business and costs and cope with R&D and commercial challenges. 

Japan Results Roundup: Strong Mainstays, Currency Windfall Help Top Line

 
• By Lisa Takagi

Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US. 

Win Some, Lose Some: Amid Otsuka-Jnana Deal, Delaware Court Favors Lupin For gJynarque

 
• By Vibha Ravi

Otsuka Pharma’s acquisition of Jnana seems like a win for its pipeline, but the Japanese major faced a setback in a Delaware District Court where the judge’s opinion put challenger Lupin closer to a generic to its Jynarque (tolvaptan)

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.